tallózása szerző szerint "Laszlo V"

1-9 / 9

BARD1 serum autoantibodies for the detection of lung cancer

Pilyugin M; Descloux P; Andre PA; Laszlo V; Döme Balázs; Hegedűs, Balázs (2017)

Purpose Currently the screening for lung cancer for risk groups is based on Computed Tomography (CT) or low dose CT (LDCT); however, the lung cancer death rate has not decreased significantly with people undergoing LDCT. ...
Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma

Klikovits T; Stockhammer P; Laszlo V; Dong Y; Hoda MA; Ghanim B; Opitz I; Frauenfelder T; Nguyen-Kim TDL; Weder W; Berger W; Grusch M; Aigner C; Klepetko W; Döme, Balázs; Rényi-Vámos, Ferenc István; Oehler R; Hegedűs, Balázs (2017)

Only limited information is available on the role of complement activation in malignant pleural mesothelioma (MPM). Thus, we investigated the circulating and tissue levels of the complement component 4d (C4d) in MPM. Plasma ...
Epigenetic down-regulation of integrin alpha7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma

Laszlo V; Hoda MA; Garay, Tamás; Pirker C; Ghanim B; Klikovits T; Dong YW; Rózsás, Anita; Kenessey, István; Szirtes, Ildikó; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zochbauer-Muller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Döme, Balázs; Hegedűs, Balázs (2015)

Malignant pleural mesothelioma (MPM) is a devastating malignancy characterized by invasive growth and rapid recurrence. The identification and inhibition of molecular components leading to this migratory and invasive ...
Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis

Kirschner MB; Pulford E; Hoda MA; Rózsás, Anita; Griggs K; Cheng YY; Edelman JJ; Kao SC; Hyland R; Dong Y; Laszlo V; Klikovits T; Vallely MP; Grusch M; Hegedűs, Balázs; Döme, Balázs; Klepetko W; van Zandwijk N; Klebe S; Reid G (2015)

BACKGROUND: Fibulin-3 (FBLN3) was recently presented as a promising novel biomarker for malignant pleural mesothelioma (MPM), warranting independent validation studies. METHODS: ELISA was used to measure cellular and ...
Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study

Ghanim B; Klikovits T; Hoda MA; Lang, György; Szirtes, Ildikó; Setinek U; Rozsas A; Rényi-Vámos, Ferenc István; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz, Tibor; Döme, Balázs; Hegedűs, Balázs (2015)

BACKGROUND: Estimating the prognosis in malignant pleural mesothelioma (MPM) remains challenging. Thus, the prognostic relevance of Ki67 was studied in MPM. METHODS: Ki67 index was determined in a test cohort of 187 cases ...
Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors

Torok S; Rezeli M; Kelemen O; Vegvari A; Watanabe K; Sugihara Y; Tisza A; Marton T; Kovacs I; Tovari J; Laszlo V; Helbich TH; Hegedűs, Balázs; Klikovits T; Hoda MA; Klepetko W; Paku S; Marko-Varga G; Dome B (2017)

Resistance mechanisms against antiangiogenic drugs are unclear. Here, we correlated the antitumor and antivascular properties of five different antiangiogenic receptor tyrosine kinase inhibitors (RTKIs) (motesanib, pazopanib, ...
Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells.

Garay, Tamás; Kenessey, István; Molnár, Eszter; Juhasz E; Réti, Andrea; Laszlo V; Rozsas A; Dobos J; Döme, Balázs; Berger W; Klepetko W; Tóvári, József; Tímár, József; Hegedűs, Balázs (2015)

While targeted therapy brought a new era in the treatment of BRAF mutant melanoma, therapeutic options for non-BRAF mutant cases are still limited. In order to explore the antitumor activity of prenylation inhibition we ...
Quantitative LA-ICP-MS imaging of platinum in chemotherapy treated human malignant pleural mesothelioma samples using printed patterns as standard

Bonta M; Lohninger H; Laszlo V; Hegedűs Balázs; Limbeck A (2014)
Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations

Garay, Tamás; Molnár, Eszter; Juhasz E; Laszlo V; Barbai, Tamás; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár, József; Hegedűs, Balázs (2015)

BRAF and NRAS are the two most frequent oncogenic driver mutations in melanoma and are pivotal components of both the EGF and FGF signaling network. Accordingly, we investigated the effect of BRAF and NRAS oncogenic mutation ...

1-9 / 9

Keresés

Összetett keresés

Tallózás

Teljes repozitórumban

Hozzáférésem

Bejelentkezés

tallózása szerző szerint "Laszlo V"

DSpace/Manakin Repository

tallózása szerző szerint "Laszlo V"

Keresés

Tallózás

Teljes repozitórumban

Hozzáférésem